Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (SHA:688076)

China · Delayed Price · Currency is CNY

27.43

+0.29 (1.07%)

Jun 18, 2026, 3:00 PM CST

-27.13% (1Y)

Market Cap	8.67B -29.5%
Revenue (ttm)	1.93B +5.2%
Net Income	309.27M -37.0%
EPS	0.98 -38.4%
Shares Out	316.05M
PE Ratio	28.05
Forward PE	n/a
Dividend	0.35 (1.28%)
Ex-Dividend Date	Jun 12, 2026

Volume	2,070,120
Open	27.14
Previous Close	27.14
Day's Range	26.68 - 27.77
52-Week Range	26.68 - 50.86
Beta	0.34
Analysts	Strong Buy
Price Target	58.57 (+113.53%)
Earnings Date	Aug 21, 2026

About SHA:688076

Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd., a biomedical company, engages in the research and development, production, and sale of peptides, oligonucleotides, and small molecule drugs in China. The company offers Peptide CDMO Services,GMP oligo, full-time equivalent, discovery, generic APIs, and formulation services. It is also involved in professional technical services. The company was founded in 2009 and is headquartered in Hangzhou, China. [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 2,247

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688076

Full Company Profile

Financial Performance

In 2025, SHA:688076's revenue was 1.94 billion, an increase of 19.57% compared to the previous year's 1.62 billion. Earnings were 332.42 million, a decrease of -17.80%.

Financial Statements